Lexaria Bioscience (LEXX.Q) announced today that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The VIRAL-A20-3 study was performed using Sprague-Dawley rats, with…
Latest News
Tesla stock to $100?
Top 5 Gainers and Losers: KASH.CN, DHR.V, BRO.V
Standard Uranium (STND.V) looks to add to Sun Dog’s uranium history
Top 5 Gainers and Losers: SEI.V, LAB.V, NCU.TO
West High Yield Resources (WHY.V) announces milestone for Magnesium Project
Top 5 Gainers and Losers: GXU.V, SANU.CN, BTR.V